Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $5.2050 (-4.67%) ($5.2050 - $5.2050) on Tue. Jan. 4, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.95% (three month average) | RSI | 41 | Latest Price | $5.2050(-4.67%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | AUTL declines -2.3% a week on average for past two weeks. | Market Behavior | Rotation from growth to value for large cap. Rotation from growth to value for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) XBI(66%) IBB(60%) IBUY(59%) ARKG(56%) ARKK(55%) | Factors Impacting AUTL price | AUTL will decline at least -2.475% in a week (0% probabilities). VIXM(-40%) VXX(-33%) TLT(-23%) SHY(-22%) TIP(-18%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.475% (StdDev 4.95%) | Hourly BBV | -0.8 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-13.31(-355.72%) | Resistance Level | $5.63 | 5 Day Moving Average | $5.26(-1.05%) | 10 Day Moving Average | $5.3(-1.79%) | 20 Day Moving Average | $5.63(-7.55%) | To recent high | -26.1% | To recent low | 1.7% | Market Cap | $272m | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |